Cabozantinib for Liver Cancer

Recruiting in Palo Alto (17 mi)

Overseen by Jennifer J. Knox, MD, MSc

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: University Health Network, Toronto

Must not be taking: Anticoagulants

Disqualifiers: Brain metastases, Cardiovascular disorders, GI disorders, others

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests cabozantinib in patients with liver cancer who had a liver transplant but whose cancer has returned. Cabozantinib works by blocking proteins that help cancer cells grow. The goal is to see if this drug can control the disease in these patients.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently receiving other investigational agents or using anticoagulants at therapeutic doses.

What data supports the effectiveness of the drug Cabozantinib for liver cancer?

Cabozantinib has been shown to improve overall survival and progression-free survival in patients with advanced liver cancer who had previously been treated with another drug called sorafenib. This was demonstrated in a large study called the CELESTIAL trial, which led to its approval for this use in both Europe and the USA. ^{1 2 3 4 5}

What is the safety profile of Cabozantinib for liver cancer treatment?

Cabozantinib, used for advanced liver cancer, can cause side effects like hand-foot syndrome (skin reaction on palms and soles), high blood pressure, tiredness, and diarrhea. These side effects are common but can be managed with dose adjustments and supportive care. ^{2 3 6 7 8}

How is the drug cabozantinib unique for treating liver cancer?

Cabozantinib is unique for treating liver cancer because it is a multikinase inhibitor that targets specific proteins involved in cancer growth, such as VEGF, MET, and AXL receptors. It is particularly used for patients with advanced liver cancer who have already been treated with sorafenib, offering improved survival rates compared to placebo. ^{2 3 4 9 10}

Research Team

Jennifer J. Knox, MD, MSc

Principal Investigator

Princess Margaret Cancer Centre

Eligibility Criteria

Adults who've had a liver transplant to treat hepatocellular carcinoma (liver cancer) but now have recurrence. They should not have tried cabozantinib before, may have had one prior therapy for advanced cancer, and must be able to swallow pills. Excluded are those with recent treatments, other serious health issues like infections or heart problems, pregnant women, or anyone with conditions that might interfere with the trial.

Inclusion Criteria

Have histologically or cytologically confirmed hepatocellular carcinoma that has recurred.

No prior treatment with cabozantinib. May be systemic therapy naïve or have received up to 1 line of prior therapy for advanced HCC with sorafenib or lenvatinib.

Agree to use effective contraceptive methods until at least 30 days (for women) and 3 months (for men) after the last administration of study medication. Serum pregnancy test should be negative

Exclusion Criteria

Other clinically significant disorders: Active infection requiring systemic treatment, known infection with human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)-related illness, Serious non-healing wound/ulcer/bone fracture, Malabsorption syndrome, Uncompensated/symptomatic hypothyroidism, Requirement for hemodialysis or peritoneal dialysis, Pregnant women

Patients with a grade >= 2 elevated liver enzymes who are suspected of cellular rejection will undergo biopsy. Patients diagnosed with cellular rejection in the biopsy sample using the Banff schema are ineligible

Active hepatitis B or C in liver graft

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Several visits (in-person)

Study Drug Period

Participants receive cabozantinib as prescribed, with weekly clinic visits for tests and assessments

Until no longer beneficial or intolerable side effects occur

Weekly visits (in-person)

End of Study Drug Visit and Follow-up

Participants have an End of Study Drug visit 30 days after the last dose, followed by follow-up visits every 8 weeks

30 days for End of Study Drug visit, then every 8 weeks for follow-up

1 visit (in-person) for End of Study Drug, then every 8 weeks (in-person)

Treatment Details

Interventions

• Cabozantinib (Tyrosine Kinase Inhibitor)

Trial Overview The study is testing cabozantinib's effectiveness in controlling recurrent liver cancer after a transplant. It targets proteins involved in tumor growth. Participants will take this drug until it stops working for them or side effects become too severe.

Participant Groups

Group I: Cabozantinib Experimental Treatment 1 Intervention

Cabozantinib, at a dose of 60 mg orally (by mouth), once a day (at bedtime), continuously.

Cabozantinib is already approved in Canada, Japan for the following indications:

Approved in Canada as Cabometyx for:

• Renal cell carcinoma
• Hepatocellular carcinoma

Approved in Japan as Cabometyx for:

• Renal cell carcinoma

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials

1,555

Recruited

526,000+

Dr. Brad Wouters

University Health Network, Toronto

Chief Medical Officer since 2020

MD from University of Toronto

Dr. Kevin Smith

University Health Network, Toronto

Chief Executive Officer since 2018

Professor at McMaster University and University of Toronto

Ipsen

Industry Sponsor

Trials

358

Recruited

74,600+

David Loew

Ipsen

Chief Executive Officer since 2020

BA in Business Administration and MBA from the University of St. Gallen, Switzerland

Sandra Silvestri

Ipsen

Chief Medical Officer since 2023

MD, PhD

Findings from Research

In a study of 26 patients with unresectable hepatocellular carcinoma treated with cabozantinib, both full-dose (60 mg) and reduced-dose (40 or 20 mg) groups showed similar efficacy, with objective response rates of 6.7% and 9.1%, respectively.

The reduced-dose group experienced significantly fewer side effects, such as decreased appetite and fatigue, suggesting that lower doses of cabozantinib may be a safer treatment option without compromising effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Tomonari, T., Tani, J., Ogawa, C., et al.[2023]

Cabozantinib (Cabometyx®) is now approved as a first-line treatment for advanced renal cell carcinoma (RCC) in treatment-naïve adults, expanding its use beyond patients who have already received VEGF-targeted therapy.

In a phase 2 trial, cabozantinib significantly improved median progression-free survival and objective response rates compared to the standard treatment sunitinib, while its side effects are manageable, similar to other tyrosine kinase inhibitors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. Lyseng-Williamson, KA.[2020]

References

1. Netherlands pubmed.ncbi.nlm.nih.gov

Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. [2023]

2. New Zealand pubmed.ncbi.nlm.nih.gov

Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. [2021]

3. France pubmed.ncbi.nlm.nih.gov

Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. [2020]

4. England pubmed.ncbi.nlm.nih.gov

Cabozantinib as a second-line treatment option in hepatocellular carcinoma. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

New Indication for Cabozantinib. [2023]

6. United States pubmed.ncbi.nlm.nih.gov

Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. [2020]

7. England pubmed.ncbi.nlm.nih.gov

Cabozantinib for the treatment of hepatocellular carcinoma. [2020]

8. France pubmed.ncbi.nlm.nih.gov

Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. [2021]

9. England pubmed.ncbi.nlm.nih.gov

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. [2022]

10. New Zealand pubmed.ncbi.nlm.nih.gov

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. [2020]